Navigation Links
HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
Date:4/21/2009

Collaboration will leverage HUYA's growing Chinese bioscience network

SAN DIEGO, April 21 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.

Abbott will gain access to HUYA's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates.

"China has an extremely rich pool of drug candidates, which we are able to tap through our extensive network of partners," said Mireille Gingras, PhD, President and CEO of HUYA. "We've been effective in leveraging those relationships to the mutual benefit of our partners in the West and in China, and we're looking forward to a productive collaboration with Abbott."

HUYA's model is based on long-term relationships with its Chinese partners and this provides a continuous source of compounds, unlike a single compound strategy. Once a compound is licensed, the ongoing exchange of expertise and data lowers risk and facilitates rapid and efficient clinical development in both China and the West.

HUYA currently has two clinical stage drugs licensed from China in the therapeutic areas of Cardiovascular and Oncology for development in the West.

HUYA's innovative model benefits partners in the West and China

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. HUYA identifies and licenses highly promising pre-clinical and clinical stage compounds in China and provides access to those compounds to partners in the West. Likewise, HUYA provides a valuable bridge to Western development for its partners in China. HUYA's Chinese partners retain development and marketing rights in China with the expectation that both parties will benefit from the research and development collaboration.

One of the key differentiators of HUYA's approach is the assembly of a high-level team of scientific and clinical advisors for each new compound. The team collaborates with its Chinese partners to discuss and design pre-clinical tests and clinical trials as the compounds enter the U.S. development process, speeding the process and mitigating risk. HUYA's global team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD, Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.

"HUYA has forged highly productive relationships with its Chinese partners, which sets up the potential for clinical development and new treatment options in several diseases," said Eric Topol, Chief Academic Officer, Scripps Health, San Diego, CA.

About HUYA

HUYA is a leader in U.S./China pharmaceutical co-development with four strategic offices in China, a broad Chinese compound portfolio, and a significant number of exclusive agreements with premier Chinese biotech centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.

Contact:

    USA:
    Jan Tuttleman, PhD
    Vice President, Marketing
    HUYA Bioscience International, LLC
    (858) 798-8800
    jtuttleman@huyabio.com

    China:
    Li Zhu, PhD
    VP China Operations
    HUYA Bioscience International, LLC
    86 (21) 51323312

Media Contact:

    Juliet Travis
    (510) 452-3771
    juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Biosciences Launches Next-Generation Protein Characterization System
2. Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution
3. Cell Biosciences Announces Publication in Nature Medicine
4. Cell Biosciences Closes $10 Million Series C Financing
5. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
6. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
7. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
8. Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
9. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
10. Three Firms, Two Training Programs Garner Greater Baltimore Committees 2009 Bioscience Awards
11. PURE Bioscience Schedules Second Quarter 2009 Financial Results Conference Call for March 12, 2009 at 1:30 P.M. PDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will ... conference in San Francisco’s Moscone Center from February 16-18, 2016, and at the ... These latest InGaAs PIN diode standard packages feature a TO-46 metal can with active ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... is now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing ... saw clear demand for Microsoft Azure from major institutions collecting and analyzing genomic ...
(Date:2/10/2016)... Vancouver, BC (PRWEB) , ... February 09, 2016 ... ... and design services and current winner of the Highest Overall Customer Rating ... certification in all of its business units across the USA, Canada, Mexico and ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: March ... at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, Doylestown, ... (TCMC) will hold an open house for participants to learn about a new ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
Breaking Biology News(10 mins):